Immune Checkpoint Inhibitors Can Be Active in Penile Cancer
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 23, 2023 -- Immune checkpoint inhibitors (ICIs) are active in some patients with penile cancer (PeCa), according to a study published online Aug. 11 in the Journal of the National Cancer Institute.
Talal El Zarif, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues conducted a retrospective study including 92 patients with locally advanced or metastatic PeCa receiving ICIs during 2015 to 2022 across 24 centers in the United States, Europe, and Asia. Overall survival (OS) and progression-free survival (PFS) were estimated, and objective response rates (ORRs) were determined.
Overall, 28, 25, 17, and 16 percent of patients received pembrolizumab monotherapy, combination nivolumab/ipilimumab with or without multitargeted tyrosine kinase inhibitors, nivolumab, or cemiplimab monotherapies, respectively. The researchers found that the median OS was 9.8 months and median PFS was 3.2 months. ORR was 13 and 35 percent in the overall cohort and for those with lymph node-only metastases. Worse OS was seen in association with visceral metastases, Eastern Cooperative Oncology Group performance status ≥1, and higher neutrophil/lymphocyte ratio. Treatment-related adverse events occurred in 29 percent of participants; 9.8 percent were grade 3 or higher.
"The study highlights the importance of high-quality, real-world research to advance therapeutic options for this rare cancer," El Zarif said in a statement. "We are hopeful that response and survival rates will continue to improve for patients fighting penile cancer."
Several authors disclosed ties to the biopharmaceutical and medical technology industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Nudging Both Clinicians, Patients May Increase Serious Illness Conversations
TUESDAY, July 2, 2024 -- Combining clinician- and patient-directed nudges may help to promote serious illness conversations (SICs) in cancer care, according to a study published...
Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant...
Racial Differences Seen in Financial Hardship Among Older Cancer Survivors
MONDAY, July 1, 2024 -- Income and area-level disadvantage are the largest contributors to racial differences in financial hardship among older U.S. adults with cancer, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.